Repurposing Siponimod for Alzheimer's Disease (NCT06639282)
SIPO1-AD: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Siponimod in Patients With Mild Alzheimer's Disease
๐ฉบ Plain-English Summary (8th-Grade Level)
Collaboration with multiple sclerosis (MS) specialty colleagues led us to formulate the central hypothesis that Siponimod could lower the rate of brain atrophy in Alzheimer's disease (AD) subjects. To test our central hypothesis, we will carry out an 18-month Phase II, double-blind, randomized, twoarmed, placebo controlled, proof-of-concept clinical study in early AD subjects (i.e. mild AD) who will be receiving an escalating dose of Siponimod or placebo in the ratio 2:1 for 12 months, followed by a 6-month washout period. The primary outcome measures are safety and tolerability of Siponimod in mild AD subjects. The secondary outcome measures are the rates of brain atrophy derived from volumetric MRI (vMRI) as a proxy for neurodegeneration conducted at baseline, 6, 12, and 18 months. The tertiary outcome measures are the changes in cognition and the levels of AD-associated (e.g., Aฮฒ and tau) and inflammatory biomarkers in CSF after Siponimod exposure. In an exploratory effort, we will also measure plasma inflammatory markers during the entire duration of the study to investigate whether one or more of these markers can be used as dynamic surrogate markers of treatment response. Using our unique experience with the repurposing of immunomodulatory drugs for AD (and NCT #04032626), in the present project we are using elements of clinical trial design that we believe were successful and made some adjustments to fit the pharmacologic and toxic properties of Siponimod.
Who can join: Review the eligibility criteria below.
Location: St. Joseph's Hospital and Medical Center โ Phoenix, Arizona
Age range: 50 Years to 85 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- St. Joseph's Hospital and Medical Center โ Phoenix, Arizona
๐ Contact the Study Coordinator
Phone: (602) 406-7735
Email: Marwan.Sabbagh@CommonSpirit.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alzheimer Disease
- The Use of Memantine for Prevention of Alzheimer's Disease โ Charlottesville, Virginia
- Investigation of Inflammation Using [C-11]-CS1P1 โ St Louis, Missouri
- Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia โ Palo Alto, California
- A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study) โ Gilbert, Arizona
- High Frequency Light and Sound Stimulation to Improve Brain Functions in Alzheimer's Disease โ Cambridge, Massachusetts
- A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease โ Phoenix, Arizona
Explore by condition: All Alzheimer Disease clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.